Cargando…

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)

BACKGROUND: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a spectrum of histological changes in PDAC. Different grading regression sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Redegalli, M., Schiavo Lena, M., Cangi, M. G., Smart, C. E., Mori, M., Fiorino, C., Arcidiacono, P. G., Balzano, G., Falconi, M., Reni, M., Doglioni, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072515/
https://www.ncbi.nlm.nih.gov/pubmed/35230580
http://dx.doi.org/10.1245/s10434-022-11413-7
_version_ 1784701079122870272
author Redegalli, M.
Schiavo Lena, M.
Cangi, M. G.
Smart, C. E.
Mori, M.
Fiorino, C.
Arcidiacono, P. G.
Balzano, G.
Falconi, M.
Reni, M.
Doglioni, C.
author_facet Redegalli, M.
Schiavo Lena, M.
Cangi, M. G.
Smart, C. E.
Mori, M.
Fiorino, C.
Arcidiacono, P. G.
Balzano, G.
Falconi, M.
Reni, M.
Doglioni, C.
author_sort Redegalli, M.
collection PubMed
description BACKGROUND: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a spectrum of histological changes in PDAC. Different grading regression systems are currently available; unfortunately, they lack precision and accuracy. We aimed to identify a new quantitative prognostic index based on tumor morphology. PATIENTS AND METHODS: The study population was composed of 69 patients with resectable or borderline resectable PDAC treated with preoperative NACT (neoadjuvant group) and 36 patients submitted to upfront surgery (upfront-surgery group). A comprehensive histological assessment on hematoxylin and eosin (H&E) stained sections evaluated 20 morphological parameters. The association between patient survival and morphological variables was evaluated to generate a prognostic index. RESULTS: The distribution of morphological parameters evaluated was significantly different between upfront-surgery and neoadjuvant groups, demonstrating the effect of NACT on tumor morphology. On multivariate analysis for patients that received NACT, the predictors of shorter overall survival (OS) and disease-free survival (DFS) were perineural invasion and lymph node ratio. Conversely, high stroma to neoplasia ratio predicted longer OS and DFS. These variables were combined to generate a semiquantitative prognostic index based on both OS and DFS, which significantly distinguished patients with poor outcomes from those with a good outcome. Bootstrap analysis confirmed the reproducibility of the model. CONCLUSIONS: The pathologic prognostic index proposed is mostly quantitative in nature, easy to use, and may represent a reliable tumor regression grading system to predict patient outcomes after NACT followed by surgery for PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11413-7.
format Online
Article
Text
id pubmed-9072515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-90725152022-05-07 Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) Redegalli, M. Schiavo Lena, M. Cangi, M. G. Smart, C. E. Mori, M. Fiorino, C. Arcidiacono, P. G. Balzano, G. Falconi, M. Reni, M. Doglioni, C. Ann Surg Oncol Pancreatic Tumors BACKGROUND: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a spectrum of histological changes in PDAC. Different grading regression systems are currently available; unfortunately, they lack precision and accuracy. We aimed to identify a new quantitative prognostic index based on tumor morphology. PATIENTS AND METHODS: The study population was composed of 69 patients with resectable or borderline resectable PDAC treated with preoperative NACT (neoadjuvant group) and 36 patients submitted to upfront surgery (upfront-surgery group). A comprehensive histological assessment on hematoxylin and eosin (H&E) stained sections evaluated 20 morphological parameters. The association between patient survival and morphological variables was evaluated to generate a prognostic index. RESULTS: The distribution of morphological parameters evaluated was significantly different between upfront-surgery and neoadjuvant groups, demonstrating the effect of NACT on tumor morphology. On multivariate analysis for patients that received NACT, the predictors of shorter overall survival (OS) and disease-free survival (DFS) were perineural invasion and lymph node ratio. Conversely, high stroma to neoplasia ratio predicted longer OS and DFS. These variables were combined to generate a semiquantitative prognostic index based on both OS and DFS, which significantly distinguished patients with poor outcomes from those with a good outcome. Bootstrap analysis confirmed the reproducibility of the model. CONCLUSIONS: The pathologic prognostic index proposed is mostly quantitative in nature, easy to use, and may represent a reliable tumor regression grading system to predict patient outcomes after NACT followed by surgery for PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11413-7. Springer International Publishing 2022-03-01 2022 /pmc/articles/PMC9072515/ /pubmed/35230580 http://dx.doi.org/10.1245/s10434-022-11413-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pancreatic Tumors
Redegalli, M.
Schiavo Lena, M.
Cangi, M. G.
Smart, C. E.
Mori, M.
Fiorino, C.
Arcidiacono, P. G.
Balzano, G.
Falconi, M.
Reni, M.
Doglioni, C.
Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
title Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
title_full Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
title_fullStr Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
title_full_unstemmed Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
title_short Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
title_sort proposal for a new pathologic prognostic index after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma (pinc)
topic Pancreatic Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072515/
https://www.ncbi.nlm.nih.gov/pubmed/35230580
http://dx.doi.org/10.1245/s10434-022-11413-7
work_keys_str_mv AT redegallim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT schiavolenam proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT cangimg proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT smartce proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT morim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT fiorinoc proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT arcidiaconopg proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT balzanog proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT falconim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT renim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc
AT doglionic proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc